GSK’s Myeloma Drug Gets AdComm Backing, But Limitations Remain Clear
Likely To Be First BCMA Approval
Executive Summary
The antibody-drug conjugate now looks set for US approval, but its limitations leave plenty of scope for CAR-T and bispecific rivals.
You may also be interested in...
GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
EMA Says Yes To GSK’s Belantamab But Rejects Tagraxofusp & Emapalumab
GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.
Concerns About Eye Toxicity Could Limit GSK’s Myeloma Drug Potential
Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.